Vertaling van "prevention of adverse effects and adverse " (Nederlands → Frans) :

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.

Table 3: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)
Table 5: Update of evidence found in SR and HTA Search Radiation harms of mammography screening (40-49 y) questions Note Update of HTA (ETMIS) Date 03/05/2010 Keywords Breast neoplasms, mammography/ adverse effects, mass screening/ adverse effects Medline Case report.tw (156081) (OVID): 2 Letter.pt (689184) Filter 3 Historical article.pt (263481) RCT 4 Review of reported cases.pt (0) 5 Review,multicase.pt (0) 6 or/1-5 (1099551) 7 Breast/ or Breast Diseases/ (30731) 8 Neoplasms/ (216844) 9 7 and 8 (536) 10 exp Breast Neoplasms/ (171800) 11 (breast$ adj5 neoplas$).tw (2557) 12 (breast$ adj5 cancer$).tw (135752) 13 (breast$ adj5 carcin$).tw (31777) 14 (breast$ adj5 tumo$).tw (23441) 15 (breast$ adj5 metasta$).tw (16582) 16 (breast$ adj5 malig$).tw (7361) 17 exp Carcinoma, Ductal, Breast/ (8472) 18 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (207367) 19 Mammography/ae [Adverse Effects] (517) 20 Mass Screening/ae [Adverse Effects] (325) 21 19 or 20 (763) 22 18 and 21 (443) 23 22 not 6 (379) 24 limit 23 to (yr=" 2005 -Current" and " all adult (19 plus years)" and (dutch or english or french)) (44) 25 from 24 keep 1-44 (44)

Vaccination Vaccination/adverse vaccinatie Vaccination effect Under 18 years Infant, child, Beneden 18 jaar Moins de 18 adolescent ans Epinephrine Epinephrine Adrenaline Adrenaline Prevention Accident Prevention Treatment Therapeutics Behandeling Traitement * MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.
Vaccination Vaccination/adverse Vaccinatie Vaccination effect Under 18 years Infant,Child, Beneden 18 jaar Moins de 18 Adolescent ans Epinephrine Epinephrine Adrenaline Adrenaline CPR Cardiopulmonary Reanimatie Réanimation Resuscitation Prevention Accident Prevention Preventie Prévention Treatment Therapeutics Behandeling Traitement * MeSH (Medical Subject Headings) is the NLM controlled vocabulary thesaurus used for indexing articles for PubMed.

AAA aromatic amino acids aromatische aminozuren ADH aanbevolen dagelijkse hoeveelheid AR average requirement gemiddelde behoefte ATP adenosinetrifosfaat BMI body mass index BMR basal metabolic rate basaal metabolisme CLA conjugated linoleic acid geconjugeerd linolzuur DHA docosahexaëenzuur ΔE energievoorraad EAZ essentieel aminozuur EI energie-inname EPA eicosapentaëenzuur EV energieverbruik FAD flavineadenine-dinucleotide FMN flavine-mononucleotide GTF glucose tolerance factor glucose tolerantie factor His histidine IE internationale eenheid IEI integrated energy index geïntegreerde energie-index Ile isoleucine LA linolzuur LDL low density lipoprotein lage dichtheid lipoproteïne Leu leucine lg lichaamsgewicht LNA alfa-linoleenzuur LOAEL lowest observed adverse effect level LTI lowest treshold intake laagste opname-drempel Lys lysine MAO monoamineoxydase MUFA mono unsaturated fatty acids enkelvoudig onverzadigde vetzuren NHANES III third national health and nutrition examination survey NOAEL no observed adverse effect level NPU net protein utilisation netto eiwit benutting NSP non starch polysaccharides niet-zetmeel polymere koolhydraten
AAA aromatic amino acids acides aminés aromatiques AAE / AAI acide aminé essentiel / indispensable ADMR average daily metabolic rate AE apport énergétique AET apport énergétique total AJR apport journalier recommandé AR average requirement besoin moyen ATP adénosine triphosphate BMI body mass index BMR basal metabolic rate métabolisme basal (ou de base) CLA conjugated linoleic acid acide linoléique conjugué DE dépense énergétique DHA acide docosahexaénoïque ΔE réserve énergétique EPA acide eicosapentaénoïque ER équivalent rétinol ES énergie stockée FAD flavine adénine dinucléotide FMN flavine mononucléotide GTF glucose tolerance factor facteur de tolérace au glucose His histidine IEI integrated energy index indice énergétique intégré Ile isoleucine IQ Quetelet index indice de Quetelet (ou BMI) LDL low density lipoprotein lipoprotéine à faible densité Leu leucine LOAEL lowest observed adverse effect level LTI lowest treshold intake seuil d’apport le plus bas LA acide linoléique LNA acide linolénique Lys lysine MAO monoamine-oxydase MUFA mono unsaturated fatty acids acides gras monoinsaturés NHANES III third national health and nutrition examination survey NOAEL no observed adverse effect level NPU net protein utilisation utilisation protéique nette NSP non starch polysaccharides polysaccharides non amylacés PAI physical activity index PAL physical activity level niveau d’activité physique PAR physical activity ratio ratio d’activité physique p.c. poids corporel PDCAAS protein digestibility-corrected amino acid score

In de Lescol Intervention Prevention Study (LIPS) werd het effect van fluvastatine op ernstige ongewenste cardiale voorvallen (MACE - major adverse cardiac events, d.w.z. cardiaal overlijden, nietfataal myocardinfarct en coronaire revascularisatie) geëvalueerd bij patiënten met coronair hartlijden die eerder een succesvolle percutane coronaire interventie hadden ondergaan.
Au cours de l’étude LIPS (Lescol Intervention Prevention Study, Etude Prévention Intervention Lescol), l’effet de la fluvastatine sur les effets indésirables cardiaques majeurs (EICM, c.-à-d. décès d’origine cardiaque, infarctus du myocarde non fatal et revascularisation coronaire) a été évalué chez des patients atteints d’une cardiopathie ischémique ayant d’abord subi avec succès une intervention coronaire percutanée.

Lijst van de gebruikte afkortingen EFSA: European Food Safety Authority EU : Europese Unie FOD : Federale Overheidsdienst FSA : British Food Standards Agency HGR : Hoge Gezondheidsraad LOAEL : Lowest Adverse Effect Level NOAEL: No Observed Adverse Effect Level OIVO : Onderzoeks- en Informatiecentrum van de Verbruikersorganisaties RPE : Ratings of Perceived Exertion SCF : Scientific Committee on Food UL : tolerable Upper intake Level WIV : Wetenschappelijk Instituut Volksgezondheid
Liste des abréviations CRIOC : Centre de Recherche et d'Information des Organisations de Consommateurs CSS : Conseil Supérieur de la Santé EFSA: European Food Safety Authority FSA : British Food Standards Agency ISP : Institut Scientifique de Santé Publique LOAEL : Lowest Adverse Effect Level NOAEL: No Observed Adverse Effect Level RPE : Ratings of Perceived Exertion SCF : Scientific Committee on Food SPF : Service public fédéral UE : Union Européenne UL : tolerable Upper intake Level

The evaluation of oncological adverse effects (as well as the evaluation of the Periodic Safety Update Report – PSUR, Annual Safety Report - ASR, Suspected Unexpected Serious Adverse Reaction
The evaluation of oncological adverse effects (as well as the evaluation of the Periodic Safety Update Report – PSUR, Annual Safety Report - ASR, Suspected Unexpected Serious Adverse Reaction

Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete
Healthcare professionals and consumers of medicines and health products need to be made aware of the utility and obligation (in the case of materiovigilance and haemovigilance) of reporting adverse effects and adverse events associated with the use of medicines and health products to the FAMHP. Furthermore, the report form should be made easy to complete

Het verslag van de risicobeoordeling die in de Scandinavische landen werd uitgevoerd door Meltzer et al (2008) en die betrekking heeft op de cafeïne-inname bij kinderen en tieners maakte het mogelijk om de volgende waarden te identificeren: (1) een NOAEL (No Observed Adverse Effet Level) van 0,3 mg/kg/dag voor de ontwikkeling van cafeïnetolerantie en (2) een LOAEL (Lowest Adverse Effect Level) van 1 tot 1,25 mg/kg/dag voor de ontwikkeling van cafeïnetolerantie, van 2,5 mg/kg/dag voor het ontstaan van angstgevoelens en van 1,4 mg/kg/dag voor het ontstaan van slaapstoornissen.
Le rapport de d’évaluation du risque de la consommation de caféine réalisé par Meltzer et al (2008) dans les pays nordiques et qui concerne les enfants et adolescents a permis l’identification des valeurs suivantes : un NOAEL (No Observed Adverse Effet Level) de 0,3 mg/kg/j pour le développement de la tolérance à la caféine et un LOAEL (Lowest Adverse Effect Level) de 1 à 1,25 mg/kg/j pour le développement de la tolérance à la caféine, de 2,5 mg/kg/j pour le développement de l’anxiété et de 1,4 mg/kg/j pour le développement de troubles du sommeil.